Advertisement

Journal of Neuro-Oncology

, Volume 26, Issue 3, pp 209–219 | Cite as

The clinical significance of malfunction of the CD44 locus in malignancy

  • D. Tarin
  • J. Bolodeoku
  • S. J. Hatfill
  • T. Sugino
  • A. C. Woodman
  • K. Yoshida
Section II: CD44 Expression in Human Systemic Tumors

Conclusions

This brief overview indicates that a large amount of intriguing information has emerged in the last few years about the unusual activity of the CD44 gene in neoplasia. It is a large gene and potentially could produce the most alternative splicing combinations yet described for any locus [1]. Although it is not yet known whether some of these are biologically inadmissable, several different isoforms containing various exon combinations have so far been detected. Therefore, it is likely that unravelling whether the observed disturbances in its regulation are causally involved in tumour induction and/or progression, or are merely consequences of other events, will take much time and effort.

From a clinical standpoint the observations already made by several independent groups indicate that derangements at the CD44 locus may be sufficiently frequent and consistent to be a useful marker for early detection of certain types of malignancy. Further studies will establish whether or not there is a direct link between expression of certain CD44 splice variants and tumour invasion or metastasis. The results could have implications for evaluation of prognosis of individual patients in clinical work, but it is too early to comment further. Given that many genes show tissue specific patterns of expression in adult organs, it is possible that the detection of abnormal CD44 activity may only have clinical utility for tumour detection in some sites and not others. Even so, the results which have accumulated to date indicate that further investigation of the pleomorphic activities of this unusual gene may provide data which illuminate the pathogenesis of aggressive neoplastic behaviour. The clinical challenge is to try to convert the fundamental and promising information so far obtained into practical advances in the early diagnosis and treatment of malignancy.

Key words

RT-PCR CD44s CD44v metastasis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI: Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89: 12160–12164, 1992Google Scholar
  2. 2.
    Hofmann M, Rudy W, Zoller M, Tolg C, Ponta H, Herrlich P, Gunthert U: CD44 splice variants confer metastatic behaviour in rats: Homologous sequences are expressed in human tumor cell lines. Cancer Res 51: 5292–5297, 1991Google Scholar
  3. 3.
    Dougherty GJ, Lansdorp PM, Cooper DL, Humphries RK: Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocytes ‘homing’ receptor expressed by hemopoietic cells. J Exp Med 174: 1–5, 1991Google Scholar
  4. 4.
    Jalkanen S, Jalkanen M, Bargatze R, Tammi M, Butcher EC: Biochemical properties of glycoproteins involved in lymphocyte recognition of high endothelial venules in man. J Immunol 141: 1615–1623, 1988Google Scholar
  5. 5.
    Brown RA, Bouchard T, St John T, Wayner E, Carter WG: Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biol 113: 207–221, 1991Google Scholar
  6. 6.
    Stamenkovic I, Amiot M, Pesando JM, Seed B: A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 56: 1057–1062, 1989Google Scholar
  7. 7.
    Lesley J, Hyman R, Kincade PW: CD44 and its interaction with the extracellular matrix. Adv Immunol 54: 271–335, 1993Google Scholar
  8. 8.
    Stamenkovic I, Aruffo A, Amiot M, Seed B: The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potentials for hyaluronatebearing cells. EMBO J 10: 343–348, 1991Google Scholar
  9. 9.
    Gunthert U, Hofmann M, Rudy W, Reber S, Zoller M, Haümann I, Matzku S, Wenzel A, Ponta H, Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65: 13–24, 1991Google Scholar
  10. 10.
    Jackson DG, Buckley J, Bell JI: Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. J Biol Chem 267: 4732–4739, 1992Google Scholar
  11. 11.
    Matsumura Y, Tarin D: Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 340: 1053–1058, 1992Google Scholar
  12. 12.
    Matsumura Y, Hanbury D, Smith J, Tarin D: Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. BMJ 308: 619–624, 1994Google Scholar
  13. 13.
    Kaufmann M, Heider K-H, Sinn H-P, von Minckwitz G, Ponta H, Herrlich P: CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345: 615–619, 1995Google Scholar
  14. 14.
    Fox SB, Fawcett J, Jackson DG, Collins I, Gatter KC, Harris AL, Gearing A, Simmons DL: Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 54: 4539–4546, 1994Google Scholar
  15. 15.
    Joensuu H, Klemi PJ, Toikkanen S, Jalkanen S: Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 143: 867–874, 1993Google Scholar
  16. 16.
    Bolodeoku J, Yoshida K, Yeomans P, Wells CA, Tarin D: Demonstration of CD44 gene expression in cells from fine needle aspirates (FNA) of breast lesions by the polymerase chain reaction following reverse transcription J Clin Pathol Mol Pathol (in press)Google Scholar
  17. 17.
    Tanabe KK, Nishi T, Saya H: Novel variants of CD44 arising from alternative splicing: Changes in the CD44 alternative splicing pattern of MCF-7 breast carcinoma cells treated with hyaluronidase. Molecular Carcinogenesis 7: 212–220, 1993Google Scholar
  18. 18.
    Watson PH, Snell LS: CD44 expression and oestrogen receptor status in breast cancer. Proc Am Assoc Cancer Res 35: p83 (abstract) 495, 1994Google Scholar
  19. 19.
    Culty M, Shizari M, Thompson EW, Underhill CB: Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: Correlation with invasive potential. J Cell Physiol 160: 275–286, 1994Google Scholar
  20. 20.
    Abbasi AM, Chester KA, Talbot IC, Macpherson AS, Boxer G, Forbes Aet al.: CD44 is associated with proliferation in normal and neoplastic human colorectal epithelial cells. Eur J Cancer 29A(14): 1995–2002, 1993Google Scholar
  21. 21.
    Tanabe KK, Ellis LM, Saya H: Expression of CD44R1 adhesion molecule in colon carcinomas and metastases. Lancet 341: 725–726, 1993Google Scholar
  22. 22.
    Finn L, Becich M, Dougherty G, Finley G, Meisler A, Cooper D: CD44 alternative splicing in human colon carcinomas. Lab Invest 68: 49A, 1993Google Scholar
  23. 23.
    Heider K-H, Hofmann M, Hors E, van den Berg F, Ponta H, Herrlich P, Pals ST: A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 120: 227–233, 1993Google Scholar
  24. 24.
    Wielenga VJM, Heider K-H, Offerhaus GJA, Adolf GR, van den Berg FM, Ponta H, Herrlich P, Pals ST: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 53: 4754–4756, 1993Google Scholar
  25. 25.
    Yang XL, Kim H, Rosada C, Hamilton S, August JT: Expression of CD44 splice variant isoforms is an early event in colorectal neoplasia. In: Proc Am Assoc Cancer Res 35: p216 (Abstract 1290), 1994Google Scholar
  26. 26.
    Yokozaki H, Ito R, Nakayama H, Kuniyasu H, Taniyama K, Tahara E: Expression of CD44 abnormal transcripts in human gastric carcinomas. Cancer Lett 83: 229–234, 1994Google Scholar
  27. 27.
    Heider K-H, Dammrich J, Skroch-Angel P, Muller-Hermelink H-K, Vollmers HP, Herrlich P, Ponta H: Differential expression of CD44 splice variants in intestinal- and diffusetype human gastric carcinomas and normal gastric mucosa. Cancer Res 53: 4197–4203, 1993Google Scholar
  28. 28.
    Tahara E: Molecular mechanisms of stomach carcinogenesis. J Cancer Res Clin Oncol 119: 265–272, 1993Google Scholar
  29. 29.
    Chaudry A, Gobl A, Eriksson B, Skogseid B, Oberg K: Different splice variants of CD44 are expressed in gastrinomas but not in other subtypes of endocrine pancreatic tumors. Cancer Res 54: 981–986, 1994Google Scholar
  30. 30.
    Mulder J-WT, Kruyt PM, Sewnath M, Oosting J, Seldenrijk CA, Weidema WF, Offerhaus GJA, Pals ST: Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 344:1470–1472, 1994Google Scholar
  31. 31.
    Guo Y-J, Liu G, Wang X, Jin D, Wu M, Ma J, Sy M-S: Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54: 422–426, 1994Google Scholar
  32. 32.
    Terpe H, Koopman R, Imhof BA, Gunthert U: Expression of integrins and CD44 isoforms in non-Hodgkins lymphoma: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas. J Pathol 174: 89–100, 1994Google Scholar
  33. 33.
    Moller P, Eichelmann A, Leithauser P, Mechtersheimer G, Otto HF: Venular endothelium binding molecules CD44 and LECAM-1 in normal and malignant B-cell populations. Virchows Arch A Pathol Anat Histopathol 421: 305–313, 1992Google Scholar
  34. 34.
    Arch R, Wirth K, Hofmann M, Ponta H, Matzku S, Herrlich P, Zoller M: Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science 257: 682–685, 1992Google Scholar
  35. 35.
    Haynes BF, Telen MJ, Hale LP, Denning SM: CD44-a molecule involved in leukocyte adherence and T cell activation. Immunol Today 10: 423–428, 1989Google Scholar
  36. 36.
    O'Neill HC: Antibody which defines a subset of BM cells that can migrate to thymus. Immunol 68: 59–65, 1989Google Scholar
  37. 37.
    Wu L, Kincade PW, Shortman K: The CD44 expressed on the earliest thymic precursor population functions as a thymus homing molecule but does not bind to hyaluronate. Immunol Lett 38: 69–75, 1993Google Scholar
  38. 38.
    Kansas GS, Dailey MO: Expression of adhesion structures during B-cell development in man. J Immunol 142: 3058–3062, 1989Google Scholar
  39. 39.
    Picker LJ, Medeiros LJ, Weiss LM, Warnke RA, Butcher EC: Expression of lymphocyte homing receptor antigen in non-Hodgkin's lymphoma. Am J Pathol 130: 496–504, 1988Google Scholar
  40. 40.
    Ristamaki R, Joensuu H, Salmi M, Jalkanen S: Serum CD44 in malignant lymphoma: an association with treatment response. Blood 84: 238–243, 1994Google Scholar
  41. 41.
    Koopman G, Heider K-H, Horst E, Adolf GR, van den Berg F, Ponta H, Herrlich P, Pals ST: Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44. J Exp Med 177: 897–904, 1993Google Scholar
  42. 42.
    Dall P, Heider K-H, Hekele A, von Minckwitz G, Kaufmann M, Ponta H, Herrlich P: Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. Cancer Res 54: 3337–3341, 1994Google Scholar
  43. 43.
    Cancer Research Campaign Factsheet 1.2, 1990Google Scholar
  44. 44.
    Sugiyama M, Woodman A, Sugino T, Crowley S, Ho K, Smith J, Matsumura Y, Tarin D: Non-invasive detection of bladder cancer by identification of abnormal CD44 proteins in exfoliated cancer cells in urine. J Clin Path (in press)Google Scholar
  45. 45.
    Matsumura Y, Sugiyama M, Matsumura S, Hayle AJ, Robinson P, Smith JC, Tarin D: Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol (in press)Google Scholar
  46. 46.
    Liu AY: Expression of CD44 in prostate cancer cells. Cancer Lett 76: 63–69, 1994Google Scholar
  47. 47.
    Penno MB, August JT, Baylin SB, Mabry M, Linnoila RI, Lee VS, Croteau D, Yang XL, Rosada C: Expression of CD44 in human lung tumors. Cancer Res 54: 1381–1387, 1994Google Scholar
  48. 48.
    Clarke MR, Landreneau RJ, Resnick NM, Crowley R, Dougherty G, Cooper DL, Youssem SA: Prognostic significance of CD44 expression in adenocarcinoma of the lung. J Clin Path (in press)Google Scholar
  49. 49.
    Jackson DG, Schenker T, Waibel R, Bell JI, Stahel RA: Expression of alternatively spliced forms of the CD44 extracellular-matrix receptor on human lung carcinomas. Int J Cancer Suppl 8: 110–115, 1994Google Scholar
  50. 50.
    Birch M, Mitchell S, Hart IR: Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44. Cancer Res 51: 6660–6667, 1991Google Scholar
  51. 51.
    Sy MS, Guo Y-J, Stamenkovic I: Distinct effects of two CD44 isoforms on tumor growthin vivo. J Exp Med 174: 859–866, 1991Google Scholar
  52. 52.
    Mayer B, Jauch KW, Gunthert U, Figdor CG, Schildberg F, Funke I, Johnson JP: Lancet 342: 1019–1022, 1993Google Scholar
  53. 53.
    Washington K, Gottfried MR, Telen MJ: Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas. Hum Pathol 25: 1043–1049, 1994Google Scholar
  54. 54.
    Lee JH, Kang YS, Kim BG, Park SY, Lee KH, Park KB: Expression of the CD44 adhesion molecule in primary and metastatic gynecologic malignancies and their cell lines. Int J Gynecol Cancer 5: 193–199, 1995Google Scholar
  55. 55.
    Salmi M, Gron-Virta K, Sointu P, Grenman R, Kalimo H, Jalkanen S: Regulated expression of exon v6 containing isoforms of CD44 in man: Downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol 122: 431–442, 1993Google Scholar
  56. 56.
    Gross N, Beretta C, Peruisseau G, Jackson D, Simmons D, Beck D: CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation. Cancer Res 54: 4238–4242, 1994Google Scholar
  57. 57.
    Fujita N, Yaegashi N, Ide Y, Sato S, Nakamura M, Ishiwata I, Yajima A: Expression of CD44 in normal humanversus tumor endometrial tissues: Possible implication of reduced expression of CD44 in lymph-vascular space involvement of cancer cells. Cancer Res 54: 3922–3928, 1994Google Scholar
  58. 58.
    Shtivelman E, Bishop JM: Expression of CD44 is repressed in neuroblastoma cells. Mol Cell Biol 11: 5446–5453, 1991Google Scholar
  59. 59.
    Robinson R, Matsumura Y, Tarin D: CD44 expression and metastasis of various human cancer cell lines in nude mice. In: Program and Abstracts of The Eighth International Conference of the International Society of Differentiation (ISD) p199 (Abstract P138), 1994Google Scholar

Copyright information

© Kluwer Academic Publishers 1995

Authors and Affiliations

  • D. Tarin
    • 1
  • J. Bolodeoku
    • 1
  • S. J. Hatfill
    • 1
  • T. Sugino
    • 1
  • A. C. Woodman
    • 1
  • K. Yoshida
    • 1
  1. 1.Nuffield Department of PathologyJohn Radcliffe Hospital, University of OxfordOxfordUK

Personalised recommendations